Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement
September 19, 2022
Signs 15-year Strategic Collaboration and Exclusive License Agreement
WALTHAM, Mass., Sept 19, 2022 — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market.
Through this agreement, Repligen will assume responsibility for the commercialization of Culpeo®, as well as the development of future products and technologies in partnership with DRS Daylight Solutions (“Daylight”). Both companies will focus on expanding the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) based solutions and integrating these solutions into Repligen Chromatography and Filtration systems to expand the companies’ presence in the fast-growing Process Analytics Technology (PAT) segment of the bioprocessing market.
Daylight’s patented QCL-IR technology measures higher order protein and nucleic acid structure, facilitating the measurement of protein aggregation, concentration and nucleic acid content and other critical attributes in biological manufacturing processes. Accurate readouts are available in seconds, enabling real-time process monitoring in upstream and downstream manufacturing.
San Diego-based Daylight specializes in the development and manufacturing of innovative solutions based on its QCL technology platform, which operates throughout the mid-IR spectral range. Daylight, known for best-in-class products supporting commercial, research, and aerospace and defense markets, entered the bioprocessing market in 2018 with its ground-breaking Culpeo® instrument.
Tony J. Hunt, Repligen CEO, said, “We are delighted to have signed this agreement with DRS Daylight Solutions, which complements our existing analytics portfolio from C Technologies, a pioneer in real-time, in-line process monitoring solutions. We believe that the Daylight portfolio will serve to accelerate and expand adoption of in-line process monitoring in the bioprocessing industry. We look forward to working with Tim Day and the team at Daylight.”
Dr. Timothy Day, Senior Vice President and General Manager, DRS Daylight Solutions, said, “We are very excited to partner with Repligen to make QCL-IR based solutions a game-changing technology in PAT. We believe Repligen is the best partner to accomplish this, given their success with C Technologies and their track record of innovation in bioprocessing. We look forward to working together with Tony Hunt and the Repligen team to provide bioprocessing customers this ground-breaking technology to measure critical process parameters in biologics manufacturing. With real-time and high reliability results, Culpeo® will ultimately improve production yields, reduce costs and ensure product quality.”
About DRS Daylight Solutions
DRS Daylight Solutions, a business unit of Leonardo DRS, is a leading provider of best-in-class, mid-IR lasers and systems for defense, commercial, and research markets. Our global leadership position in advanced, mid-IR technology means that our customers benefit from a sustainable, competitive advantage in molecular detection and imaging applications.
Leonardo DRS is headquartered in Arlington, Virginia and is a leading mid-tier provider of defense products and technologies for the U.S. military and its allies with core capabilities in advanced sensing, force protection, network computing and electric power and propulsion. For more information about Daylight, please visit our website at www.daylightsolutions.com.
About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration, Chromatography, Process Analytics, Fluid Management and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and we also have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at http://www.repligen.com. Follow us on LinkedIn and Twitter.
About Leonardo DRS
Leonardo DRS is a leading mid-tier provider of defense products and technologies for the U.S. military and its allies with core capabilities in advanced sensing, force protection, network computing and electric power and propulsion. Through its two segments, Advanced Sensing and Computing, and Integrated Mission Systems, the company is shaping the future of the battlefield. Headquartered in Arlington, Virginia, Leonardo DRS is a wholly owned subsidiary of Leonardo S.p.A. See the full range of capabilities at www.LeonardoDRS.com
On June 21, 2022 Leonardo DRS and RADA Electronic Industries Ltd. (NASDAQ & TASE: RADA) announced an all-stock merger to create a publicly-traded leader in advanced sensing and force protection. Upon completion of the transaction, the combined company expects to be listed on the Nasdaq and on the TASE under the ticker symbol “DRS”.
This communication contains statements that constitute “forward-looking statements,” including with respect to the proposed merger of DRS and RADA and its impact, if completed, on the combined company’s business. Forward-looking statements are subject to numerous conditions, many of which are beyond our control. Neither RADA nor DRS undertake any obligation to update these statements, except as required by law.
No Offer or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws of such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. This communication does not constitute an offer of securities pursuant to the Israeli Securities Law, 1968, or a recommendation regarding the purchase of securities of RADA or DRS.
ADDITIONAL INFORMATION ABOUT THE TRANSACTION AND WHERE TO FIND IT
DRS will file with the U.S. Securities and Exchange Commission (SEC) a registration statement on Form S-4, which will include a prospectus of DRS, and certain other documents in connection with the transaction. SHAREHOLDERS OF RADA ARE URGED TO READ THE PROSPECTUS AND ANY OTHER DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT DRS, RADA, THE TRANSACTION AND RELATED MATTERS. The registration statement and prospectus and other documents filed or furnished by DRS and RADA with the SEC, when filed, will be available free of charge at the SEC’s website at www.sec.gov. Alternatively, shareholders will be able to obtain free copies of the registration statement, prospectus and other documents which will be filed or furnished with the SEC by DRS by contacting DRS at +1 877-538-0912 or 2345 Crystal Drive Suite 1000 Arlington, Virginia 22202.
RADA Investor Relations Contact
EK Global Investor Relations
+1 212 378 8040
DRS Investor Relations Contact
Cody Slach or Jeff Grampp, CFA
+1 949 574 3860
Repligen Corporation Contact
Global Head of Investor Relations
DRS Media Contact
Vice President, Communications and Public Affairs
+1 571 447 4624